Hutto, David; Siontis, George C M; Noseworthy, Peter A; Siontis, Konstantinos C (2022). On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects. International Journal of Cardiology. Heart & Vasculature, 40, p. 101024. Elsevier 10.1016/j.ijcha.2022.101024
|
Text
1-s2.0-S2352906722000732-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (724kB) | Preview |
Background
Numerous observational studies support the safety and effectiveness of the direct oral anticoagulants (DOAC) for stroke prevention in atrial fibrillation (AF), but these data are often limited to short duration of follow-up. We aimed to assess the length of on-treatment follow-up in the accumulated real-world evidence and the relationship between follow-up duration and estimates of DOAC effectiveness and safety.
Methods
We searched the literature for observational studies reporting comparative effectiveness and safety outcomes of DOACs versus warfarin. In random-effects meta-analyses, we assessed associations of specific DOACs vs warfarin for stroke/systematic embolism (SE) and major bleeding. In meta-regression analyses, we assessed the correlation between the reported on-treatment follow-up with the effect sizes for stroke/SE and major bleeding outcomes.
Results
In 45 eligible observational studies, the average on-treatment follow-up was <1 year for all DOACs. In meta-analyses, all DOACs showed significantly lower risks of stroke/SE, but only dabigatran and apixaban showed lower risks for major bleeding compared to warfarin. There was no correlation between follow-up duration and magnitude of stroke/SE reduction for any of the DOACs. Longer follow-up correlated with greater major bleeding reduction for dabigatran (p = 0.006) and rivaroxaban (p = 0.033) as compared to warfarin, but it correlated with smaller major bleeding reduction for apixaban (p = 0.004).
Conclusions
The numerous studies of DOAC effectiveness and safety in the routine AF practice pertain to short treatment follow-up. Study follow-up correlates significantly with DOAC-specific vs warfarin associations for major bleeding.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Siontis, Georgios |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2352-9067 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
08 Jun 2022 11:33 |
Last Modified: |
05 Dec 2022 16:20 |
Publisher DOI: |
10.1016/j.ijcha.2022.101024 |
PubMed ID: |
35663450 |
Uncontrolled Keywords: |
Anticoagulants Atrial fibrillation Duration of therapy Factor Xa inhibitors Warfarin |
BORIS DOI: |
10.48350/170468 |
URI: |
https://boris.unibe.ch/id/eprint/170468 |
Actions (login required)
 |
Edit item |